Literature DB >> 27933465

Nano-Mechanical Characterization of Ataxia Telangiectasia Cells Treated with Dexamethasone.

Michele Menotta1, Sara Biagiotti2, Giulia Bartolini2, Bianchi Marzia2, Sara Orazi2, Aldo Germani3, Luciana Chessa3, Mauro Magnani2.   

Abstract

Ataxia telangiectasia is a rare genetic disease and no therapy is currently available. Glucocorticoid analogues have been shown to improve the neurological symptoms of treated patients. In the present study ataxia telangiectasia and wild type cells were used as a cellular model and treated with dexamethasone. The cells were subsequently investigated for membrane and whole cell mechanical properties by atomic force microscopy. In addition, cytoskeleton protein dynamics and nuclear shapes were assayed by fluorescence microscopy, while western blots were used to assess actin and tubulin content. At the macro level, dexamethasone directly modified the cell shape, Young's modulus and cytoskeleton protein dynamics. At the nano level, the roughness of the cell surface and the local nano-mechanical proprieties were found to be affected by Dexa. Our results show that ataxia telangiectasia and wild type cells are affected by Dexa, although there are dissimilarities in some macro-level and nano-level features between the tested cell lines. The Young's modulus of the cells appears to depend mainly on nuclear shape, with a slight contribution from the tested cytoskeleton proteins. The current study proposes that dexamethasone influences ataxia telangiectasia cell membranes contents, cell components and cell shape.

Entities:  

Keywords:  Ataxia telangiectasia; Atomic force microscopy; Dexamethasone; Young’s modulus

Mesh:

Substances:

Year:  2016        PMID: 27933465     DOI: 10.1007/s12013-016-0775-0

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  6 in total

1.  In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia.

Authors:  Michele Menotta; Sara Biagiotti; Sara Orazi; Luigia Rossi; Luciana Chessa; Vincenzo Leuzzi; Daniela D'Agnano; Alessandro Plebani; Annarosa Soresina; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2017-07-25       Impact factor: 3.396

2.  The positive short-term effect of dexamethasone on ataxia symptoms in a patient with ataxia-telangiectasia: A case report.

Authors:  Maryam Saberi-Karimian; Mehran Beyraghi-Tousi; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Clin Case Rep       Date:  2022-05-20

3.  The nucleoplasmic interactions among Lamin A/C-pRB-LAP2α-E2F1 are modulated by dexamethasone.

Authors:  Anastasia Ricci; Sara Orazi; Federica Biancucci; Mauro Magnani; Michele Menotta
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

4.  Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38.

Authors:  Sara Biagiotti; Marzia Bianchi; Luigia Rossi; Luciana Chessa; Mauro Magnani
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.240

5.  ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T.

Authors:  Michele Menotta; Sara Biagiotti; Chiara Spapperi; Sara Orazi; Luigia Rossi; Luciana Chessa; Vincenzo Leuzzi; Daniela D'Agnano; Annarosa Soresina; Roberto Micheli; Mauro Magnani
Journal:  Orphanet J Rare Dis       Date:  2017-07-05       Impact factor: 4.123

6.  Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with Dexamethasone.

Authors:  Michele Menotta; Sara Orazi; Anna Maria Gioacchini; Chiara Spapperi; Anastasia Ricci; Luciana Chessa; Mauro Magnani
Journal:  PLoS One       Date:  2018-04-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.